Abstract
There is a need for new oral agents active against extended-spectrum beta-lactamase (ESBL) producers, as these increasingly cause community-onset infections. We therefore evaluated faropenem, a penem in Phase III development, against recently collected oxyimino-cephalosporin-resistant bacteria.
Original language | English |
---|---|
Pages (from-to) | 1025-30 |
Number of pages | 6 |
Journal | Journal of Antimicrobial Chemotherapy |
Volume | 59 |
Issue number | 5 |
DOIs | |
Publication status | Published - May 2007 |
Keywords
- Anti-Bacterial Agents
- Cephalosporin Resistance
- England
- Enterobacteriaceae
- Humans
- Microbial Sensitivity Tests
- beta-Lactams